Results 61 to 70 of about 26,436 (212)

Advanced In Vitro Platforms for Experimental Liver Research: From Organoids and Liver‐on‐Chip to Omics and Artificial Intelligence

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Hepatocytes perform essential physiological functions in the human body. Gaining more profound insight into the liver structure, diseases, and physiology by using in vitro models can help to propose more relevant clinical applications. Conventional in vitro liver models, such as two‐dimensional (2D) cell cultures, fail to adequately replicate ...
Seyedeh Kiana Teymorian, Pedram Asadi Sarabi, Abbas Piryaei, Massoud Vosough   +3 more
wiley   +1 more source

Aurora-A promotes lenvatinib resistance experimentally through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma

International Journal of Immunopathology and Pharmacology
Objective: This study aimed to investigate whether the dysregulation of Aurora-A is involved in lenvatinib resistance in hepatocellular carcinoma. Methods: Bioinformatics tools and drug sensitivity assays were used to investigate the association between ...
Mubalake Abudoureyimu, Ni Sun, Weiwei Chen, Xinrong Lin, Fan Pan, Rui Wang   +5 more
doaj   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis

, 2023
Aims To investigate the efficacy and safety of lenvatinib and idarubicin‐loaded drug‐eluting beads transarterial chemoembolization (IDADEB‐TACE) in primary advanced hepatocellular carcinoma (HCC).
Xinlin Zheng, Xinhua Zou, Yiyang Tang, Fuliang Li, Liangliang Qiao, Hongyu Wang, Miao Xue, Shufan Yue, Yanqin Wu, Jiaping Li, Bowen Zhu, Wenzhe Fan   +11 more
core   +1 more source

Time‐Dependent Bias and Prognostic Confounding in Exposure–Response Analysis of Targeted Therapies: Lessons from Sunitinib in Metastatic Renal Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Exposure–response (E–R) analyses of sunitinib in metastatic renal cell carcinoma (mRCC) have supported concentration‐guided dose escalation. However, such analyses may be biased when exposure metrics incorporate post‐baseline dose modifications, time‐varying apparent clearance, or baseline factors that influence both pharmacokinetics and clinical ...
Han Liu, Lena E. Friberg
wiley   +1 more source

Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications

Journal of Experimental & Clinical Cancer Research
Background Lenvatinib, a tyrosine kinase receptor inhibitor, has emerged as a frontline therapeutic strategy for the management of advanced hepatocellular carcinoma (HCC). However, the modest response rate observed with lenvatinib and the rapid emergence
Bixing Zhao, Yang Zhou, Niangmei Cheng, Xiaoyuan Zheng, Geng Chen, Xin Qi, Xiangzhi Zhang, Fei Wang, Qiuyu Zhuang, Yehuda G. Assaraf, Xiaolong Liu, Yingchao Wang, Yongyi Zeng   +12 more
doaj   +1 more source

A Computed Tomography Radiomics Approach for Assessing the T Cell‐Inflamed Gene Expression Profile in Hepatocellular Carcinoma and Its Association With Immunotherapy Response

Health Care Science, EarlyView.
The T cell‐inflamed gene expression profile (GEP) provides a biomarker for immunotherapy response across various cancers. We established a CT‐based radiomics model to predict the T cell‐inflamed GEP and immunotherapy response in hepatocellular carcinoma (HCC).
Mimi Tang, Kaiyu Sun, Dasheng Wu, Yujian Zou, Jian Zhou, Bin Li, Huanjing Hu, Zhenpeng Peng, Jifei Wang, Bingsheng Huang, Shi‐Ting Feng, Shuling Chen   +11 more
wiley   +1 more source

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy lenvatinib alone for advanced hepatocellular carcinoma

Therapeutic Advances in Medical Oncology, 2021
Background: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but prognosis is still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and immune checkpoint inhibitors showed promising results for ...
Min-Ke He, Run-Bin Liang, Yang Zhao, Yu-Jie Xu, Huan-Wei Chen, Yuan-Min Zhou, Zhi-Cheng Lai, Li Xu, Wei Wei, Yao-Jun Zhang, Min-Shan Chen, Rong-Ping Guo, Qi-Jiong Li, Ming Shi   +13 more
doaj   +1 more source

Lenvatinib targets STAT-1 to enhance the M1 polarization of TAMs during hepatocellular carcinoma progression

BMC Cancer
Lenvatinib, a multitarget kinase inhibitor, has been proven to be effective in the treatment of advanced hepatocellular carcinoma. It has been previously demonstrated that tumour associated macrophages (TAMs) in tumour tissues can promote HCC growth ...
Peng Sun, Zhenfeng Li, Zaojun Yan, Zhaofeng Wang, Peng Zheng, Mingliang Wang, Xu Chang, Zihao Liu, Jianxin Zhang, Huiyong Wu, Wenbo Shao, Dewen Xue, Jinming Yu   +12 more
doaj   +1 more source

ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential

iNew Medicine, EarlyView.
ATP citrate lyase (ACLY) is a central metabolic hub that diverts mitochondrial citrate to fuel de novo lipogenesis, cholesterol biosynthesis, and protein acetylation. Given its robust correlation with pathological changes in multiple human diseases, ACLY inhibitors featuring distinct pharmacological strengths have been developed for therapeutic ...
Wenbiao Wang, Xinyan Li, Honglu Shi, Gaolei Song, Zhifu Xie, Jingya Li   +5 more
wiley   +1 more source